Abstract: The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPAR? agonist, INT131 and optionally vitamin E or compositions thereof. NAFLDs that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH). Lipodystrophic syndromes that may be treated with the methods and compositions of the present invention include, but are not limited to, generalized lipodystrophy including congenital generalized lipodystrophy and acquired generalized lipodystrophy and/or partial lipodystrophy, including congenital partial lipodystrophy and acquired partial lipodystrophy, all of which may or may not include hyperlipidemia and/or hyperglycemia and may or may not include NAFLD.

Abstract: The present invention is related to synthesis of highly pure cationic surfactant products by eliminating or reducing impurities generation that has beset prior art. This is achieved through the N-acylation of ester of amino acid and its inorganic salts or its organic salts (e.g. amino acid or hydrochloride of amino acid or sulfate of amino acid or acetate of amino acid etc.) in non-hydrolytic or nearly non-hydrolytic reaction conditions involving mono or biphasic reaction system with fatty acid halide (C4 to C20), under moderate uniform basic condition yielding high purity N-acyl substituted amino acid ester, particularly ethyl lauroyl arginate. The present process achieves pH control through process strategy rather than the measurement and control steps. This ambient temperature process is stable through a range of temperature variation eliminating rigid low temperature control.

Abstract: A means of isolating specific stereoisomers and enantiomers from a complex mixture containing a possibility of 32 different stereoconfigurations, thus concentrating the stereoisomer or enantiomer to a high degree of purity.

Abstract: Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.

Abstract: The present invention relates generally to abuse-deterrent formulations containing dextroamphetamine sulfate.

Abstract: Provided herein are pharmacologically active compositions suitable for topical application or injection directly for fat treatment without the need for surgical intervention.

Abstract: Disclosed herein are methods and systems for the simultaneous production of oxo-alcohols comprising n-butanol, isobutanol, and 2-ethylhexanol. Also disclosed are methods and systems for simultaneous production of plasticizers using the disclosed oxo-alcohols.

Abstract: The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.

Abstract: A process for preparing alkanesulfonic acids from sulfur trioxide and an alkane, wherein sulfur trioxide, the alkane and dialkylsulfonoyi peroxide (DASP) react as components, characterized in that the following steps are performed: a) sulfur trioxide is charged in a high-pressure reactor in a condensed phase; b) a temperature of at least 25° C. is set; c) the gaseous alkane is introduced to the high-pressure reactor until a pressure of at least 10 bar is reached; d) dialkylsulfonoyi peroxide (DASP) is added; and e) after a duration of at least 5 hours, the produced alkanesulfonic acid is withdrawn.

Abstract: The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I), Formula (II), and Formula (V) are provided.

Abstract: Provided herein are non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 and type 2 (17?-HSD1 and 17?-HSD2) inhibitors, their production and use, especially for the treatment and for prophylaxis of hormone-related diseases.

Abstract: The present disclosure provides for a composition which may be used for the solublization of an agent or the oral administration of an agent, the composition comprising, a lyosphosphatidyl compound and at least one of a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises a lyosphosphatidyl compound, a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises an agent, a lyosphosphatidyl compound, a monoglyceride and a free fatty acid.

Abstract: The present invention provides a pharmaceutical composition for preventing and/or treating a movement disorder comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating movement disorder.

Abstract: The present invention relates to the use of aromatic boronic acid or borinic acid derivatives in organic electronic devices, in particular electroluminescent devices.

Abstract: This invention relates to a process for obtaining highly pure aliphatic dialkyl esters of saturated dicarboxylic acids from vegetable oils, which can advantageously be used in polymerization. The process comprises the steps of reacting with an aliphatic alcohol a triglycerides mixture containing at least one triglyceride of at least one saturated dicarboxylic acid in the presence of one or more catalysts capable of catalyzing the esterification and transesterification reactions, and separating the dialkyl esters of saturated dicarboxylic acids from the reaction mixture thus obtained.

Abstract: The present invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.

Abstract: An acrylic or methacrylic compound having N-alkoxyalkyl group; and a method for producing the compound. An acrylic or methacrylic compound having N-alkoxyalkyl group, of Formula [1]: [where R1 is a hydrogen atom or methyl group; R2 is a C2-20 alkylene group etc.; R3 is an r-valent C2-20 aliphatic group etc.; R4 is a C1-20 alkyl group etc.; Z is >NCOO— or —OCON< (where “-” is a bond, “>” and “<” each have two bonds, and any one of “>” and “<” is bonded to —CH2OR4); and r is a natural number of 2 or more and 9 or less].

Abstract: Xylylene dicarbamate contains impurities represented by formulas (1) to (4) below at a ratio of less than 100 ppm as a total amount thereof on a mass basis. (In the above-described formulas (1) to (4), R represents a monovalent hydrocarbon group.).

Abstract: A treatment method including: (a) identifying a subject in need of treatment for androgenic alopecia (AGA), and (b) orally administering a physiologically effective amount of cepharanthine (CEP) to the subject according to a dosage regimen.

Abstract: Described herein are antimicrobial compounds identified via a high-throughput screen to identify compounds that produce anucleate cells in E. coli after cell division occurs. Compound 1 (5-nonyloxytryptamine) and its analogs are small molecule inhibitors of the nucleoid occlusion system and/or proteins that are responsible for maintaining the structure of the chromosome. The antimicrobial compounds are useful to treat bacterial infections as well as to inhibit bacterial growth.